Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 5/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 3/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | PRNP | P04156 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 2/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL951102 | 0.90 | NR3C2 (0.36) | NR3C2HSD17B10NPSR1KDM4EALDH1A1 | |
| SCHEMBL12528609 | 0.87 | ALDH1A1 (0.36) | TSHRHSD17B10NPSR1KDM4EALDH1A1 | |
| SCHEMBL30961134 | 0.85 | PDE10A (0.34) | NR3C2NPSR1ELANE | |
| SCHEMBL27257407 | 0.85 | RAB9A (0.34) | NR3C2ELANE | |
| SCHEMBL27256457 | 0.85 | PDE10A (0.34) | NR3C2NPSR1ELANE | |
| SCHEMBL12912044 | 0.79 | ELANE (0.35) | TSHRHSD17B10NPSR1KDM4EHTT | |
| SCHEMBL12912024 | 0.79 | TSHR (0.36) | TSHRHSD17B10NPSR1KDM4EHTT | |
| SCHEMBL12912004 | 0.79 | HTT (0.35) | TSHRHSD17B10NPSR1KDM4EALDH1A1 | |
| SCHEMBL12911953 | 0.76 | PTGS1 (0.47) | TSHR | |
| SCHEMBL12911837 | 0.73 | RXRA (0.46) | NR3C2MEN1KMT2AELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7867949-B2 | Hydrazide compound and pesticidal use of the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-01-11 | — | — | US | disclosed |
| US-20090181956-A1 | Hydrazide Compound and Pesticidal Use of the Same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181956-A1 | Hydrazide Compound and Pesticidal Use of the Same | ACHE, DDT, CAT | NR3C2 3760/4885TSHR 1774/4885HSD17B10 619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.